癌症患者对比剂相关急性肾损伤风险模型的开发与验证:基于46,000余次CT检查的评估
这项回顾性多中心研究纳入了25,184例癌症患者共46,593次增强CT检查,开发并验证了一个预测对比剂相关急性肾损伤(CA-AKI)的风险评分模型。模型包含血液系统恶性肿瘤、利尿剂使用、ACEI/ARB使用、CKD分期、低白蛋白血症、血小板减少、蛋白尿、糖尿病、心力衰竭及对比剂用量≥100 mL等变量,评分范围0-53分。
要点
- 增强CT后CA-AKI总体发生率为5.8%(2682/46,593次检查)。
- 风险评分最高分值(13分)来自CKD 4-5期和白蛋白<3.0 g/dL。
- 验证集低风险组(≤4分)CA-AKI发生率2.2%,高风险组(≥30分)达32.7%。
局限性
- 回顾性研究设计。
- 原文未报告外部独立验证队列,仅在同一研究内部进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Patients with cancer undergo frequent CT examinations with iodinated contrast media and may be uniquely predisposed to contrast-associated acute kidney injury (CA-AKI). OBJECTIVE. The purpose of this study was to develop and validate a model for predicting the risk of CA-AKI after contrast-enhanced CT in patients with cancer. METHODS. This retrospective study included 25,184 adult patients (12,153 men, 13,031 women; mean age, 62.3 ± 13.7 [SD] years) with cancer who underwent 46,593 contrast-enhanced CT examinations between January 1, 2016, and June 20, 2020, at one of three academic medical centers. Information was recorded regarding demographics, malignancy type, medication use, baseline laboratory values, and comorbid conditions. CA-AKI was defined as a 0.3-mg/dL or greater increase in serum creatinine level from baseline within 48 hours after CT or a 1.5-fold or greater increase in the peak measurement within 14 days after CT. Multivariable models accounting for correlated data were used to identify risk factors for CA-AKI. A risk score for predicting CA-AKI was generated in a development set (n = 30,926) and tested in a validation set (n = 15,667). RESULTS. CA-AKI occurred after 5.8% (2682/46,593) of CT examinations. The final multivariable model for predicting CA-AKI included hematologic malignancy, diuretic use, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, chronic kidney disease (CKD) stage 3a, CKD stage 3b, CKD stage 4 or 5, serum albumin level less than 3.0 g/dL, platelet count less than 150 × 103/μL, 1+ or greater proteinuria on baseline urinalysis, diabetes mellitus, heart failure, and contrast medium volume 100 mL or greater. A risk score (range, 0-53 points) was generated with these variables. The most points (13) were for CKD stage 4 or 5 and for albumin level less than 3 g/dL. The frequency of CA-AKI progressively increased in higher risk categories. For example, in the validation set, CA-AKI occurred after 2.2% of CT examinations in the lowest risk category (score ≤ 4) and after 32.7% of CT examinations in the highest risk category (score ≥ 30). The Hosmer-Lemeshow test result indicated that the risk score was a good fit (p = .40). CONCLUSION. A risk model in which readily available clinical data are used to predict the likelihood of CA-AKI after contrast-enhanced CT in patients with cancer was developed and validated. CLINICAL IMPACT. The model may help facilitate appropriate implementation of preventive measures in the care of patients at high risk of CA-AKI.
引用
- Gupta, Motwani, Seitter, et al. Development and Validation of a Risk Model for Predicting Contrast-Associated Acute Kidney Injury in Patients With Cancer: Evaluation in Over 46,000 CT Examinations. AJR Am J Roentgenol. 2023. PMID: 37195792. doi:10.2214/AJR.23.29139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。